138 related articles for article (PubMed ID: 21447776)
1. PSA quo vadis? It is reasonable to start with prostate-specific antigen testing at the age of 40!
Börgermann C; vom Dorp F; Swoboda A; Ketteniss O; Becker M; Rübben H
Cancer Epidemiol Biomarkers Prev; 2011 Jun; 20(6):1190-5. PubMed ID: 21447776
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.
Berger AP; Deibl M; Steiner H; Bektic J; Pelzer A; Spranger R; Klocker H; Bartsch G; Horninger W
Prostate; 2005 Aug; 64(3):240-5. PubMed ID: 15712213
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal evaluation of prostate-specific antigen levels in a case-control study.
De Biasi F; Londero D; Praturlon S; Di Donna A; Feruglio GA; Guerra UP
Eur Urol; 1996; 29(2):184-8. PubMed ID: 8647144
[TBL] [Abstract][Full Text] [Related]
4. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.
Loeb S; Roehl KA; Antenor JA; Catalona WJ; Suarez BK; Nadler RB
Urology; 2006 Feb; 67(2):316-20. PubMed ID: 16442597
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
[TBL] [Abstract][Full Text] [Related]
6. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
7. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
[TBL] [Abstract][Full Text] [Related]
8. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
[TBL] [Abstract][Full Text] [Related]
9. Baseline prostate-specific antigen testing at a young age.
Loeb S; Carter HB; Catalona WJ; Moul JW; Schroder FH
Eur Urol; 2012 Jan; 61(1):1-7. PubMed ID: 21862205
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.
Sun L; Moul JW; Hotaling JM; Rampersaud E; Dahm P; Robertson C; Fitzsimons N; Albala D; Polascik TJ
BJU Int; 2007 Apr; 99(4):753-7. PubMed ID: 17244286
[TBL] [Abstract][Full Text] [Related]
11. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.
Schröder FH; Roobol MJ
Curr Opin Urol; 2009 May; 19(3):227-31. PubMed ID: 19357513
[TBL] [Abstract][Full Text] [Related]
12. Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening.
Hutterer G; Perrotte P; Gallina A; Walz J; Jeldres C; Traumann M; Suardi N; Saad F; Bénard F; Valiquette L; McCormack M; Graefen M; Montorsi F; Karakiewicz PI
Eur J Cancer; 2007 May; 43(7):1180-7. PubMed ID: 17292604
[TBL] [Abstract][Full Text] [Related]
13. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Culp S; Porter M
BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
[TBL] [Abstract][Full Text] [Related]
14. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
[TBL] [Abstract][Full Text] [Related]
16. Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study.
Reissigl A; Pointner J; Horninger W; Ennemoser O; Strasser H; Klocker H; Bartsch G
Urology; 1995 Nov; 46(5):662-5. PubMed ID: 7495117
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG; Pileblad E
J Urol; 2003 May; 169(5):1720-3. PubMed ID: 12686817
[TBL] [Abstract][Full Text] [Related]
18. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR
Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722
[TBL] [Abstract][Full Text] [Related]
19. Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng./ml. or less.
Harris CH; Dalkin BL; Martin E; Marx PC; Ahmann FR
J Urol; 1997 May; 157(5):1740-3. PubMed ID: 9112517
[TBL] [Abstract][Full Text] [Related]
20. [Examination of serum prostate specific antigen (PSA) in the mass screening for prostatic diseases].
Kato M; Okada K
Hinyokika Kiyo; 1993 Mar; 39(3):221-3. PubMed ID: 7685140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
